Abstract: Compounds of the general formula (I): ##STR1## where A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are defined in the description.Medicinal products.

Abstract: A compound having an aryltriazine structure selected from those of formula (I): ##STR1## for which the meaning of the substituents Ar, R.sub.1, R.sub.5, R.sub.6, and R.sub.6 ' is given in the description.The compound of the invention is useful as medicinal product for disorders associated with a cholinergic dysfunction.

Abstract: The invention relates to the compounds of general formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, A, Z and m are as defined in the description, their isomers, epimers and diastereoisomers,their addition salts with a pharmaceutically acceptable acid and, when R1 and R.sub.2 each represent a hydrogen atom, their addition salts with a pharmaceutically acceptable base.

Abstract: The invention relates to compounds of general formula I: ##STR1## in which: R.sub.1 represents a radical of general formula (Z.sub.0), (Z.sub.1), (Z.sub.2), (Z.sub.3) or (Z.sub.4) ##STR2## R.sub.2 represents a methylene radical, a hydroxymethylene radical, a carbonyl radical or a radical of general formula (Y.sub.1), (Y.sub.2), (Y.sub.3) or (Y.sub.4): ##STR3## or, with R.sub.12 and the nitrogen atom to which they are attached, forms a radical of general formula (W): ##STR4## R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12 and n being as defined in the description, medicinal products containing the same and a method-of-treating metabolic ailments therewith.

Abstract: Compounds of general formula (I): ##STR1## in which: R.sub.1 and R.sub.2 each represent a hydrogen atom or, with the nitrogen and oxygen which bear them, form an --O--CO--N link,W represents a halogen atom or a lower alkyl or alkoxy group optionally substituted with one or more halogen atoms, such as trifluoromethyl, and m being between 0 and 3,A is a linear or branched alkyl radical comprising from 1 to 6 carbon atoms,R.sub.3 and R.sub.4 are defined in the description.

Abstract: Compounds of general formula (I): in which: ##STR1## R.sub.1, X, Y, Z, T, R.sub.2, R.sub.3 and R.sub.4 are defined in the description. Medicinal products.

Abstract: Compounds of general formula (I): ##STR1## in which: R.sub.1 and R.sub.2 each represent a hydrogen atom or, with the nitrogen and oxygen which bear them, form an --O--CO--N link,W represents a halogen atom or a lower alkyl or alkoxy group optionally substituted with one or more halogen atoms, such as trifluoromethyl, and m being between 0 and 3,A is a linear or branched alkyl radical comprising from 1 to 6 carbon atoms,R.sub.3 and R.sub.4 are defined in the description have medicinal properties.

Abstract: Compounds of general formula (I): ##STR1## in which: R.sub.1 represents a hydrogen atom or a lower alkyl group,A represents a hydrogen atom, and in this case B represents a group CO-G, G being:either a heteroaryl group selected from furan, indole, pyrrole, pyridine, quinoline, isoquinoline and benzofuran, optionally substituted with one or more lower alkyl or lower alkoxy groups or a halogen atoms,or a linear or branched lower alkyl group substituted with a carboxyl group,or a linear or branched lower alkenyl group substituted with a carboxyl group,or a phenyl or naphthyl group substituted with a carboxyl group,or alternatively A forms with B a group CO(CH.sub.2).sub.n CH(CH.sub.

Abstract: The invention relates to the analgesic compounds of general formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, A, Z and m are as defined in the description, their isomers, epimers and diastereoisomers, their addition salts with a pharmaceutically acceptable acid and, when R.sub.1 and R.sub.2 each represent a hydrogen atom, their addition salts with a pharmaceutically acceptable base.

Abstract: Novel 4H-pyrrolo[1,2-a]thieno[2,3-f][1,4]diazepine which are usable as a medicinal product and correspond to the general formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the same meaning as given in the specification.These compounds, as well as their physiologically tolerable salts, may be used in therapy, in particular in the treatment of disorders linked to hypoxemia and to certain metabolic disorders.

Abstract: Compounds of general formula (I): ##STR1## in which: R.sub.1 represents a hydrogen atom or a lower alkyl group, andR.sub.2 represents a substituted or unsubstituted alkyl, a phenyl or a substituted or unsubstituted heteroaryl,their enantiomers, diastereoisomers and epimers and their addition salts with a pharmaceutically acceptable base when R.sub.1 represents a hydrogen atom or when R.sub.2 comprises a carboxylic acid group. Medicinal products.

Abstract: The subject of the invention is a novel pharmaceutical composition, especially having an anti-ischaemic action, containing, in combination, a high dosage (within the range of from 20 to 80 mg) of the dihydrochloride (or another mineral or organic salt) of 1-(2,3,4-trimethoxybenzyl)piperazine and a disintegrating agent, such as mannitol or sodium carboxymethyl starch, that has the effect of liberating the salt of 1-(2,3,4-trimethoxybenzyl)piperazine virtually instantaneously in the organism, this composition being, furthermore, advantageously enclosed in a thin coating film or held together by a binder that is itself readily disintegrated in situ in the organism in such a manner that it makes possible a "flash" action, that is to say a virtually instantaneous action, of the above-mentioned salt in situ. This composition is administered to the patient at a dosage of from 20 to 80 mg/day.